GCRF establishment of biopharmaceutical and animal vaccine production capacity in Thailand and neighbouring South East Asian countries

Lead Research Organisation: University of Kent
Department Name: Sch of Biosciences

Abstract

This programme aims to establish state of the art facilities and technology for the production of recombinant proteins, especially biopharmaceuticals and bespoke animal vaccines.

Biopharmaceuticals are protein drugs that are used to treat an increasingly wide range of serious diseases, to the extent that half of all new drugs are predicted to be biopharmaceuticals by 2020. They are usually produced in bacterial or animal cells, which makes them difficult to make and far too expensive for the vast majority of patients in developing countries. In Thailand, fewer than 2% of patients have access to anti-cancer biopharmaceuticals that are routinely used in the UK, and which are on the World Health Organisation's list of 'minimum medicine needs for a basic health-care system'. Cancer rates in Thailand are high and rising, so there is a profound need for these medicines.

Animal vaccines are required to combat infections in livestock, which is a growing problem in Thailand and other countries due to the increasing demands of growing populations. Many imported vaccines do not work well because they were raised against strains that are simply too different. Thailand and other developing countries suffer massive losses in livestock every year, with some outbreaks leading to 90% loss rates.

Countries such as Thailand can only address these problems by producing the biopharmaceuticals themselves, at much lower costs, and by formulating vaccines that are matched to circulating viral strains. Progress in both areas requires large scale facilities for recombinant protein production, usually in E. coli or mammalian cells. This is a highly complex area and most developing countries do not have this capacity - hence they need to import the products. To address this problem the Thai government has established a purpose-built National Biopharmaceutical Facility (NBF), built in 2014 and fully equipped for bacterial/ animal cell systems and product formulation. It has also developed a substantial animal vaccine research group.

The UK has world-class expertise in this area of 'bioprocessing' and this project aims to apply this expertise, initially in Thailand and later elsewhere, to develop the NBF into a state of the art facility that can make both biopharmaceuticals and vaccine antigens. The UK team includes experts in every step of the production chain, including design of expression system, expression of proteins at high levels, large scale cultivation, product extraction / purification, and product 'analysis'. The latter area is crucially important; any drugs licensed for human use have to pass extremely stringent quality tests that involve detailed analysis of the final protein product.

During the project a group of the UK applicants will work closely with the Thai team to transfer their capabilities to the Thai centres and build up production capacity. This will be aided by seconding the UK researchers to Thailand for long periods, and visits by the Thai researchers to the UK to learn new approaches. At the same time, others UK and Thai team members will work with government ministries, companies and farms to ensure that the products will be distributed effectively so that they reach end users. Finally, representatives from a range of neighbouring South East Asian countries will be involved in the network meetings so that they are fully aware of the programme's progress and outputs and able to use the information and technology to initiate their own production pipelines.

Planned Impact

The aim of this programme is to enable state of the art capacity and capability for recombinant protein production in Thailand and other South East Asian countries, with a focus on the production of (i) biopharmaceuticals and (ii) veterinary vaccines. The primary beneficiaries will be:

1. The population of Thailand, through the provision of advanced medicines and increased secure food security.
- the programme will result in a pipeline for biopharmaceutical production that is urgently needed in Thailand and neighbouring countries. The research will lead to the large-scale production of protein drugs that are routinely used to treat a number of cancer and autoimmune diseases in high-income countries. Only a small fraction (fewer than 2%) of Thai patients currently have access to these drugs but this project will result in large-scale, cost-effective production systems that will enable much greater patient penetration rates to be attained. Cancer rates, in particular, are very high in Thailand and the availability of these medicines will have a dramatic positive effect on survival rates and life expectancy for patients.
- The programme will also produce veterinary vaccines against major swine viral diseases that cause massive livestock losses. By preventing or minimising such outbreaks, the work will enhance the productivity of the Thai swine industry, provide better nutrition and safeguard jobs for approximately 200,000 households.

2. The populations of neighbouring South East Asian countries, particularly Vietnam, Cambodia, Myanmar, and Lao DPR.
- representatives from these countries will be involved in programme network meetings from the outset in order to disseminate findings at a regional level. Every assistance will be provided in order to assist these countries to start their own production facilities.
- Several Thai companies will be involved in the production, sales and marketing of these new biopharmaceuticals and vaccines, and some of these companies are large multinationals with bases in the countries listed above. This will provide a natural outlet for distribution of new products within the SE Asian region.

3. The UK Bioprocessing and animal vaccine industries and academic communities.
- while the primary impact is intended to be in SE Asia, the programme will bring together highly-rated UK groups in order to develop effective new platforms and processes for the production of these important molecules. The programme will differ from traditional production systems by focusing more intensively on cost, so that the products can be made more cheaply, ensuring that the products benefit more SE Asian end users. It is undoubtable that the establishment of integrated production processes will be of interest to UK companies and academics, who are very likely to adapt elements of the programme for their own uses. The UK houses some of the world's most prominent biopharmaceutical and animal vaccine companies, many of whom already collaborate with one or more of the applicants. The development of new expression, cultivation, downstream processing systems is certain to be of interest to such companies, as are product analysis data on the proteins that the new facilities generate.

Publications

10 25 50
 
Description The grant effectively started in January 2018 but has already produced interesting findings in terms of production of target proteins. The choice of targets has been determined through discussions with stakeholders in Thailand including the Thai Ministry of Public Health and The Health Intervention and Technology Assessment Program (HITAP) which is a semi-autonomous research unit under Thailand's Ministry of Public Health. It is a non-profit organization with responsibility for appraising a wide range of health technologies and programs.

In terms of biopharmaceuticals, we have produced CHO cell lines expressing 3 different medicines (primarily to treat breast and other cancers). We have also produced an E. coli strain expressing a biopharmaceutical to treat macular degeneration. Constructs encoding these molecules have been designed and tested at small scale, and transferred to the Thai partners who will now scale up expression.

In terms of animal vaccines, we have designed and tested constructs encoding a series of porcine vaccine candidates. Two of the constructs show high levels of expression and they have been sent to the Thai partners for further testing. Work on one of the vaccine candidates has proceeded very rapidly and we have shown that the protein expresses at high levels (over 1 gram/litre culture), and can be purified in a simple single step.

The grant is aimed at capacity building in Thailand, and the Thai partners will soon have shown that they can produce these target molecules at the required scale. We are now working with the relevant ministries in both Thailand and Vietnam to ensure that the molecules can be effectively submitted for regulatory approval once the production processes have been finalised.
Exploitation Route We are still in the early stages of the project but it is clear that several target molecules are being expressed at the required levels and we are building networks with other potential users who can benefit from this technology. Collaborations have been established with a series of groups and companies in Thailand, Malaysia and Vietnam (see list of collaborations) and this is clear progress in terms of capacity building.
Sectors Agriculture, Food and Drink,Healthcare,Government, Democracy and Justice,Manufacturing, including Industrial Biotechology,Pharmaceuticals and Medical Biotechnology

URL https://research.kent.ac.uk/gcrfbiopharma/
 
Description Previous submission: We have already engaged with key industrial and academic stakeholders in Thailand and a range of collaborations have been initiated. Key technologies used in the UK groups have been successfully transferred to both of the Thai collaborator groups. Five researchers from the Thai groups have carried out secondments at UCL and Kent to learn core techniques. Update March 2019: A range of cell lines have been generated by the UK partners and transferred to the Thai groups. They will now express the animal vaccines and biopharmaceuticals at larger scale as part of the capacity building process. We have initiated collaborations and held discussions with a very wide range fo stakeholders including major companies (CPF and BIS - see collaborations and partnerships), the Thai National Vaccines Institute, and many others. We are positioning ourselves so that when the target high-value molecules are produced at scale, they will be successfully submitted for regulatory approval and will have maximal economic and societal impact.
First Year Of Impact 2018
Sector Agriculture, Food and Drink,Healthcare,Manufacturing, including Industrial Biotechology,Pharmaceuticals and Medical Biotechnology
Impact Types Cultural,Societal,Economic,Policy & public services

 
Description Influence on Institutional attitudes to international research collaborations
Geographic Reach Asia 
Policy Influence Type Influenced training of practitioners or researchers
 
Description Influence on biopharmaceutical policy in Thailand
Geographic Reach Asia 
Policy Influence Type Influenced training of practitioners or researchers
 
Description Influence on vaccine production and purchasing policy in Thailand
Geographic Reach Asia 
Policy Influence Type Influenced training of practitioners or researchers
 
Description Royal Society Newton Advanced Fellowship
Amount £74,000 (GBP)
Organisation The Royal Society 
Sector Academic/University
Country United Kingdom
Start 10/2018 
End 09/2021
 
Title Bacterial strains expressing animal vaccines transferred to Thai collaborators 
Description This GCRF project involves production of new strains expressing animal vaccines and their transfer to Thai collaborators for scale-up. New E. coli strains expressing candidate porcine vaccines have been developed and transferred to the collaborating Thai groups 
Type Of Material Cell line 
Year Produced 2018 
Provided To Others? No  
Impact Thai collaborators will now produce the proteins at scale 
 
Title CHO cell lines expressing biopharmaceuticals + transfer to Thailand 
Description This GCRF project involves production of new strains expressing animal vaccines and their transfer to Thai collaborators for scale-up. New Chinese Hamster Ovary cell lines expressing a series of biopharmaceuticals have been developed and transferred to the collaborating Thai groups 
Type Of Material Cell line 
Year Produced 2019 
Provided To Others? No  
Impact Cell lines transferred to Thai groups for scale-up 
 
Title New E. coli strains expressing biopharmaceuticals - transfer to Thailand 
Description This GCRF project involves production of new strains expressing biopharmaceuticals and their transfer to Thai collaborators for scale-up. 2 new E. coli strains expressing biopharmaceuticals have been developed and transferred to the collaborating Thai groups 
Type Of Material Cell line 
Year Produced 2018 
Provided To Others? No  
Impact Thai groups will develop scale-up protocols 
 
Title Generation of datasets on breast cancer epidemiology in Thailand 
Description Two of the consortium PIs working in Thailand, Dr Fatim Lakha and Prof Richard Coker (employed by London School of Hygiene and Tropical Medicine) have compiled data on breast cancer from a number of sources in Thailand, including the NHSO and Cancer registry. the aim is to provide a needs assessment for the project but the report (in preparation) will provide a 10-year description of breast cancer epidemiology which will be a valuable resource in itself. 
Type Of Material Database/Collection of data 
Year Produced 2018 
Provided To Others? No  
Impact Report is in preparation 
 
Description BIOTEC 
Organisation National Center for Genetic Engineering and Biotechnology (BIOTEC)
Country Thailand 
Sector Public 
PI Contribution BIOTEC are a partner in the GCRF project who specialise in the field of animal vaccines. They are working with the UK team to develop new vaccines against porcine circoviruses
Collaborator Contribution BIOTEC provides core expertise in the design of vaccines to circovirus strains that affect SE Asia (PCV2d and PCV3). They are designing recombinant protein constructs that that UK team can produce in order to provide subunit vaccines to circulating strains of PCV2d and PCV3.
Impact Too early in the project to report specific outcomes but progress is ahead of schedule as described in other sections.
Start Year 2017
 
Description Charoen Pokphand Foods Thailand 
Organisation Charoen Pokphand Group
PI Contribution Our consortium aims to assist the Thai collaborators to design and produce porcine vaccines in Thailand and elsewhere in South East Asia. The project involves working with end users and regulatory agencies to ensure that we produce the right vaccines and to further ensure that they rapidly proceed through the regulatory approval processes.
Collaborator Contribution CPF Thailand are collaborating with our consortium on the launch of porcine vaccines. They are Thailand's largest producer of pork products and own numerous large farms. They will assist with the design and approval of vaccines against porcine viruses during the course of this project. They have close ties with key Government agencies and are in an excellent position to advise on this project.
Impact CPF are continuing to advise on the requirements for regulatory approval in Thailand and Vietnam
Start Year 2018
 
Description Chulalongkorn University 
Organisation Chulalongkorn University
Country Thailand 
Sector Academic/University 
PI Contribution Our project is aimed at capacity building of recombinant protein production in Thailand and other South East Asian countries. We provide expertise in several platforms to our core GCRF-funded partners but are also aiming to develop new collaborations with other academic and industrial partners in the region.
Collaborator Contribution Chulalongkorn University has a prominent Vaccine Research Center that aims to develop a range of new vaccines. Following initial discussions in Bangkok, they have requested a collaboration with our team in order to learn new techniques for protein production in bacterial and mammalian cell platforms. They will second a PhD student to our laboratory in Kant for 6 months starting in July 2019.
Impact Collaboration has just started
Start Year 2019
 
Description Collaboration with AlgaeCytes 
Organisation Algaecytes Limited
Country United Kingdom 
Sector Private 
PI Contribution AlgaeCytes are developing large scale cultivation systems for microalgal growth and exploitation, and our team has provided analytics expertise that allows them to characterise target product levels in their systems
Collaborator Contribution AlgaeCytes and University of Kent were involved in a FLIP exchange project that enabled close communication between partners
Impact Outputs have been enhanced algal cultivation protocols and a detailed understanding of the cultivation products in terms of target product amounts, purity and levels of contaminants
Start Year 2013
 
Description Dr Isabel Lim, University of Malaysia Sarawak 
Organisation University Malaysia Sarawak (UNIMAS)
Country Malaysia 
Sector Academic/University 
PI Contribution Dr Lim is interested in the production of novel anti-cancer products. She is collaborating with the Kent groups to test extracts from various sources for anti-cancer activity
Collaborator Contribution University of Kent has numerous cancer cell lines and will be testing extracts from Dr Lim's groups for bioactivity.
Impact Collaboration just started
Start Year 2018
 
Description Dr Zarina Amin 
Organisation Malaysian University of Sabah
Country Malaysia 
Sector Academic/University 
PI Contribution Dr Zarina Amin is Director of the Biotechnology Research Institute, University of Malaysia Sabah. Her group is now collaborating with the Kent PIs to develop vaccines against fish pathogens.
Collaborator Contribution The Malaysian fish industries (mainly Tilapia and Grouper) suffer huge losses due to bacterial infections. Dr Amin's group has started a collaboration with the Kent groups to produce recombinant subunit vaccines that are expected to be far more effective than the killed whole bacterial formulations that are currently used.
Impact Too early to report outcomes
Start Year 2018
 
Description Pongrama Ramasoota 
Organisation Mahidol University
Country Thailand 
Sector Academic/University 
PI Contribution Dr Ramasoota (Mahidol University, Thailand) has developed a monoclonal antibody against Dengue fever that is in clinical trials. However, yields from CHO cells are too low for commercialisation so our consortium is collaborating with his group to improve productivity.
Collaborator Contribution As stated above: Dr Ramasoota has developed a monoclonal antibody against Dengue fever that is in clinical trials. However, yields from CHO cells are too low for commercialisation so our consortium is collaborating with his group to improve productivity. Prof Mark Smales' group at the University of Kent are CHO cell experts who are working with Dr Ramasoota to produce super-producing cell lines.
Impact Too early in the project to report outcomes
Start Year 2018
 
Description SBS 
Organisation Siam Bioscience Co., Ltd
PI Contribution Provision of new CHO and E. coli strains and analytics expertise
Collaborator Contribution SBS are a Thai biopharmaceutical company who will be a partner in the GCRF project
Impact Collaboration started recently
Start Year 2017
 
Description Universiti Putra Malaysia 
Organisation Putra Malaysia University
Department Department of Pathology
Country Malaysia 
Sector Hospitals 
PI Contribution Our project is aimed at capacity building of recombinant protein production in Thailand and other South East Asian countries. We provide expertise in several platforms to our core GCRF-funded partners but are also aiming to develop new collaborations with other academic and industrial partners in the region.
Collaborator Contribution The collaboration is with Dr Maha Abdullah. Her group is interested in identifying and testing vaccines for the aquaculture industry in Malaysia and she has asked for assistance in the expression of a range of target proteins. The Kent group is now expressing these proteins and will send samples to Dr Abdullah for efficacy trials later this year.
Impact Collaboration just started
Start Year 2018
 
Description Vanvimon Saksmerprome 
Organisation National Center for Genetic Engineering and Biotechnology (BIOTEC)
Country Thailand 
Sector Public 
PI Contribution Dr Saksmerprome (BIOTEC) is working on vaccines against shrimp viruses. She is working with University of Kent PIs to develop new systems to combat infections.
Collaborator Contribution The Kent group is developing new methods to produce anti-viral molecules that can be used to prevent viral infections that cause massive losses in the Thai shrimp industry. She is now an 'associate partner' in the GCRF consortium. Dr Saksmerprome has recently been awarded a Newton Advanced Fellowship to work with Prof Robinson's group, significantly strengthening the collaboration.
Impact The Newton Advanced fellowship (£74,000) described above
Start Year 2017
 
Description 4th International Biotechnology and Bioengineering Conference, Kuala Lumpur 
Form Of Engagement Activity A talk or presentation
Part Of Official Scheme? No
Geographic Reach International
Primary Audience Professional Practitioners
Results and Impact This was an international conference on industrial biotechnology, attended by a wide range of academics, companies and stakeholders. I was asked to give a Plenary presentation on our research and our GCRF project
Year(s) Of Engagement Activity 2019
URL https://bioscienceconference.com/biotech-2019/
 
Description Bangkok GCRF project showcase event 
Form Of Engagement Activity Participation in an activity, workshop or similar
Part Of Official Scheme? No
Geographic Reach International
Primary Audience Policymakers/politicians
Results and Impact Our GCRF project team held a 'showcase event' In Bangkok on November 28, 2018 and the event was split into two parts:

1. Scientific session for 70-80 people on November 28, 2018, at the Sofitel Bangkok Sukhumvit. The aim was to invite senior research leaders from Thai Universities and companies, together with representatives from elsewhere in SE Asia. The event involved:
- lunch from 12-1
- talks and poster session from 1-5

2. Subsequent evening reception for 130 people at the British Embassy Residence from 7-9, to showcase the network's activities. We invited representatives from numerous government ministries, the Heads of Thai Universities and a range of other stakeholders.
Year(s) Of Engagement Activity 2018
URL https://research.kent.ac.uk/gcrfbiopharma/2018/12/17/gcrf-showcase-event-in-bangkok-brings-together-...
 
Description Bioprocessing Asia, November 2018 
Form Of Engagement Activity Participation in an activity, workshop or similar
Part Of Official Scheme? No
Geographic Reach International
Primary Audience Professional Practitioners
Results and Impact This is a major international conference held in Langkawi, Malaysia, in November 2018. One of the consortium PIs, Prof Dan Bracewell from UCL, is giving a presentation on the consortium's research
Year(s) Of Engagement Activity 2018
URL https://www.bioprocessingasia.net
 
Description GCRF Conference at University of Kent 
Form Of Engagement Activity Participation in an activity, workshop or similar
Part Of Official Scheme? No
Geographic Reach International
Primary Audience Policymakers/politicians
Results and Impact The University of Kent hosted a major GCRF conference in July 2018. It was an opportunity to learn about this significant research fund, but also to meet and work with colleagues to develop projects that would benefit those living and working in ODA-compliant countries.

The programme of the conference is available below.

Programme
The details of the programme are given below for reference. A pdf of the programme is available here. The speakers' biographies are available here. Where available, the speakers' slides are included after the title of their talks.

Monday 2 July: Understanding the context

09:00 Registration
09:30 Opening remarks
09:45 Welcome (Prof Karen Cox, the Vice Chancellor)
10:00 The GCRF and Prioritising the Most Marginalised in the Context of Global Development Challenges (Dr Jaideep Gupte, GCRF Theme Leader, UKRI) (slides - pdf)
10:30 Coffee
11:00 Global Challenges: the view from Parliament (Baroness Suttie)
11:10 The Changing Landscape of International Research Funding: opportunities, challenges and partnerships (Rachael Sara-Kennedy, Universities UK International) (slides - pdf)
11:40 Research Capacity Building in Low and Middle Income Countries (Savita Ayyar, Wellcome/DBT India Alliance, and Allen Muyaama Mukhawana, African Academy of Sciences)
12:15 Lunch
13:15 Key issues facing NGOs
A series of short talks from NGOs
AMREF Africa (slides - pdf),
Care International (slides - pdf),
Doctors with Africa (slides - pdf),
Integrity Action (slides - pdf),
Penal Reform International (slides - pdf),
Toybox (slides - pdf),
World Bicycle Relief (slides - pdf).
14:30 Coffee and networking
15:30-16:00 Optional tours of labs (Engineering and Digital Arts, Biosciences, Physical Sciences) or the campus.
17:00 Buffet and drinks reception
Tuesday 3 July: Developing projects

09:00 Opening remarks
09:15 Internationalisation in higher education (Dr Anthony Manning, Dean of Internationalisation, Kent)
09:30 Challenges and opportunities of leading a GCRF project: lessons learnt
09:30 Prof Elena Korosteleva, Principal Investigator of UKRI COMPASS (slides - pdf)
09:50 Prof Colin Robinson, Principal Investigator of the GCRF project to establish biopharmaceutical and animal vaccine production capacity in Thailand and neighbouring South East Asian countries (slides - pdf)
10:10 Dr Maria Paola Scaparra, Principal Investigator of project to understand how operational research can contribute to the achievement of the UN Sustainable Development Goals (slides - pdf)
10:30 Practical implementation of the 2030 Agenda through localising the Sustainable Development Goals (Dr Carl Wright, Commonwealth Local Government Forum)
11:00 Introduction to the Workshops (Karen Foundling, The Collective (facilitators))
11:10 Coffee
11:30 Facilitated Project Development Workshops
These will help delegates to talk openly about global challenge questions with colleagues form a range of different disciplines. The sessions will become increasingly focussed over the course of the following three and a half days
13:00 Lunch
13:45 Facilitated Project Development Workshops
Following the earlier discussions, the delegates will break into themes.
Human rights, good governance and social justice (provocateur: Harmonie Toros; expert: Elena Korosteleva; facilitator: Sarah Tetley)
Equitable access to sustainable development (provocateur: Rod Westrop (BBSRC); expert: Colin Robinson; facilitator: Helen Leech)
Sustainable economies and societies (provocateurs: John Morton & Adrienne Martin (Natural Resources Institute); expert: Maria Paola Scaparra; facilitator: Michelle Secker)
15:00 Coffee
15:30 Facilitated Project Development Workshops
17:00 Close
Wednesday 4 July: Working on the Detail and Preparing Bids

09:00 Essential Elements of Successful Funding Applications (Phil Ward, Deputy Director of Research Services) (slides - pdf)
lessons learnt by investigators and prioritisation panellists, gathered from a decade of the Grants Factory
09:45 Specific Requirements and Preparation of GCRF Bids (Dr Andrew Massoura, Grants and Contracts Manager) (slides - pdf)
What to watch out for in preparing a GCRF bid, including due diligence and post-award monitoring
10:30 Coffee
11:00 Feedback on Draft Projects
an opportunity for delegates to discuss their ideas and research questions across the three themes.
12:15 Workshops: responding to the feedback
13:00 Working Lunch
13:15 Workshops: examining specific questions
15:00 Coffee
15:30 Workshops: examining specific questions
17:00 Close
Thursday 5 July: Consolidation of the projects

09:00 Facilitated Project Development Workshops
11:00 Coffee
09:15 Facilitated Project Development Workshops
12:30 Lunch
14:00 Visit to Canterbury Cathedral
19:00 Gala dinner
Friday 6 July: Conclusion and next steps

09:00 Opening remarks
09:15 Feedback from breakout groups
10:30 Coffee
11:00 Next Steps: the University's GCRF Strategy (Dr Simon Kerridge, Director of Research Services, Kent)
11:15 Closing remarks (Prof Philippe De Wilde, Deputy Vice Chancellor Research and Innovation, Kent).
Year(s) Of Engagement Activity 2018
URL https://research.kent.ac.uk/researchservices/gcrf2018/
 
Description GCRF networks vaccinology conference, Bangkok 
Form Of Engagement Activity Participation in an activity, workshop or similar
Part Of Official Scheme? No
Geographic Reach International
Primary Audience Policymakers/politicians
Results and Impact The MRC, BBSRC, EU and WHO are holding an international conference on vaccines in Bangkok in December 2018. The consortium PI, Prof Robinson, has been invited to describe our project aims.
Year(s) Of Engagement Activity 2018
URL https://intvetvaccnet.co.uk/gcrf-networks-vaccinology-course-0
 
Description International Symposium on Human and Veterinary Viruses, Bangkok, 2018 
Form Of Engagement Activity Participation in an activity, workshop or similar
Part Of Official Scheme? No
Geographic Reach International
Primary Audience Professional Practitioners
Results and Impact This internation conference on vaccines was held in Bangkok in February 2018. A consortium members from UCL, Prof Tarit Mukhopadhyay gave a talk that introduced the consortium's aims and research.
Year(s) Of Engagement Activity 2018
 
Description Open day presentations 
Form Of Engagement Activity Participation in an open day or visit at my research institution
Part Of Official Scheme? No
Geographic Reach National
Primary Audience Schools
Results and Impact Hosted open day visits to my lab in majority of UCAS days - 2 groups of UCAS applicants + parents per open day, at least 10 open days per year

Increased understanding of biotech projects at Kent
Year(s) Of Engagement Activity 2007,2009,2011,2012,2013
 
Description Stakeholder engagement visit to Hanoi, February 2019 
Form Of Engagement Activity A formal working group, expert panel or dialogue
Part Of Official Scheme? No
Geographic Reach International
Primary Audience Policymakers/politicians
Results and Impact My visit to Hanoi during the week of February 25-March 1 was to develop collaborations with academic and industrial partners and to develop relationships with government ministries. The meetings included:
(i). Meeting with 4 executives from Charoen Pokphand Foods, Vietnam (very large producer of pork goods and hugely influential in Thailand and Vietnam). The aim was to collaborate on our consortium's production of porcine vaccines.
(ii). Presentation at the Vietnam Academy of Science and Technology and initiation of a collaboration with Dr Dang Diem Hong's group.
(iii). Meeting at the British Embassy with Science and Technology experts to start the process of interacting with the Vietnamese Ministries of Agriculture and Science.
Year(s) Of Engagement Activity 2019